查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1406711

注意力不足過動症市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、配銷通路、地區和競爭細分

Attention Deficit Hyperactivity Disorder Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Distribution Channel, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球注意力不足過動症 (ADHD) 市場價值為 153 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年CAGR為4.10%。注意力不足過動障礙(ADHD) 是一種神經發育障礙，主要影響兒童，但可能持續到青春期和成年期。其特徵是與注意力、過動和衝動相關的持續性和損害性症狀的組合。 ADHD 可以顯著影響個人的日常功能，包括他們的學業成績、人際關係和整體生活品質。患有多動症的人經常難以保持注意力和專注。他們可能難以組織任務、遵循指示以及完成作業或雜務。注意力不集中的常見症狀包括健忘、注意力不集中以及在學校或工作中經常出現粗心錯誤。 ADHD 的過動症是指過度和不適當的身體不安或活動量。對於兒童，這可能表現為難以靜坐、跑步、過度攀爬或過度說話。對於成年人來說，它可能表現為內心的不安和一種不斷「忙碌」的感覺。衝動意味著不考慮後果就採取行動。患有註意力不足過動症的人可能會在問題完成之前脫口而出、打斷別人的談話，很難等待輪到他們。衝動行為可能導致社交和學業困難。

ADHD 發病率的上升，特別是在兒童和青少年中，是一個重要的促進因素。隨著越來越多的人被診斷出患有多動症，對過動症治療的需求不斷成長。為了提高對過動症、其症狀和可用治療方法的認知，越來越多的人尋求診斷和治療。意識的提高可以推動市場的成長。改進的診斷工具和方法使識別患者的過動症變得更加容易。及時、準確的診斷是推動過動症治療需求的關鍵因素。製藥公司正在不斷研究和開發新的過動症藥物，以提高療效、安全性和便利性。新藥的推出可以刺激市場成長。 COVID-19 大流行加速了遠距醫療服務的採用，包括 ADHD 診斷和治療。遠距醫療可以改善獲得護理的機會並推動市場成長。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 153億美元
2028 年市場規模 193億美元
2023-2028 年CAGR 4.10%
成長最快的細分市場 網路藥局
最大的市場 北美洲

診斷的進步

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球注意力不足過動症 (ADHD) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型（興奮劑、非興奮劑）
    • 依配銷通路（零售藥局、醫院藥局、網路藥局）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：亞太地區注意力不足過動症 (ADHD) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國注意力不足過動症（ADHD）
    • 印度 注意力不足過動症 (ADHD)
    • 澳洲 注意力不足過動症 (ADHD)
    • 日本注意力不足過動症（ADHD）
    • 韓國 注意力不足過動症 (ADHD)

第 7 章：歐洲注意力不足過動症 (ADHD) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美注意力不足過動症 (ADHD) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：南美洲注意力不足過動症 (ADHD) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲注意力不足過動症 (ADHD) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非 注意力不足過動症 (ADHD)
    • 沙烏地阿拉伯 注意力不足過動症 (ADHD)
    • 阿拉伯聯合大公國 注意力不足過動症 (ADHD)

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球注意力不足過動症 (ADHD) 市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 15 章：大環境分析

第16章：競爭格局

  • Supernus 製藥公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 輝瑞公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 諾華公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 禮來公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 葛蘭素史克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 馬林克羅特製藥公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 強生公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 久光製藥株式會社
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 重慶富錦生物醫學公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 普渡製藥公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建議

第 18 章：關於我們與免責聲明

簡介目錄
Product Code: 19777

Global Attention Deficit Hyperactivity Disorder (ADHD) Market has valued at USD 15.30 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.10% through 2028. Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that primarily affects children but can persist into adolescence and adulthood. It is characterized by a combination of persistent and impairing symptoms related to attention, hyperactivity, and impulsivity. ADHD can significantly impact an individual's daily functioning, including their academic performance, relationships, and overall quality of life. Individuals with ADHD often struggle with sustained attention and focus. They may have difficulty organizing tasks, following instructions, and completing assignments or chores. Common signs of inattention include forgetfulness, distractibility, and frequent careless mistakes in school or work. Hyperactivity in ADHD refers to excessive and inappropriate levels of physical restlessness or activity. In children, this may manifest as difficulty sitting still, running, or climbing excessively, or talking excessively. In adults, it may manifest as inner restlessness and a sense of being constantly "on the go." Impulsivity involves acting without thinking through the consequences. Individuals with ADHD may blurt out answers before questions are completed, interrupt others in conversations, and have difficulty waiting their turn. Impulsive behavior can lead to social and academic difficulties.

The rising incidence of ADHD, particularly among children and adolescents, has been a significant driver. As more individuals are diagnosed with ADHD, there is a growing demand for ADHD treatments. Efforts to increase awareness about ADHD, its symptoms, and available treatments have led to more individuals seeking diagnosis and treatment. Increased awareness can drive market growth. Improved diagnostic tools and methods have made it easier to identify ADHD in patients. Timely and accurate diagnosis is a critical factor in driving the demand for ADHD treatments. Pharmaceutical companies are continually researching and developing new ADHD medications with improved efficacy, safety, and convenience. The introduction of novel drugs can stimulate market growth. The COVID-19 pandemic accelerated the adoption of telehealth services, including for ADHD diagnosis and treatment. Telehealth can improve access to care and drive market growth.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 15.30 Billion
Market Size 2028USD 19.30 Billion
CAGR 2023-20284.10%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Advancements in Diagnosis

The most widely used diagnostic criteria for ADHD are outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-10 and ICD-11). These criteria provide standardized guidelines for diagnosing ADHD, ensuring consistency in diagnosis. Various objective assessment tools have been developed to aid in the diagnosis of ADHD. One of the most common tools is the ADHD Rating Scale, which involves a structured interview and assessment of ADHD symptoms. Other tools, such as the Conners' Rating Scales and Vanderbilt Assessment Scales, are also frequently used. Computerized neuropsychological tests and continuous performance tests (CPTs) have been developed to assess attention, impulsivity, and executive functioning. These tests provide objective data that can assist in diagnosis. Direct observation of a person's behavior, often in a classroom or clinical setting, can be a valuable diagnostic tool. Teachers, parents, and caregivers may provide input on the individual's behavior, which is considered alongside other assessment methods. While not a primary diagnostic tool, neuroimaging techniques like functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) have provided insights into the neurological basis of ADHD. These tools can aid in research and further our understanding of the condition.

Advances in genetics and biomarker research have suggested that ADHD may have a genetic component. Although not currently used for diagnosis, ongoing research in this area may lead to the identification of genetic markers that can aid in diagnosis. Self-report scales and questionnaires, such as the Adult ADHD Self-Report Scale (ASRS), can be valuable in assessing symptoms and behaviors in adults. These tools help individuals provide information about their own experiences. A thorough developmental history, including information about early childhood behaviors and milestones, is an essential part of the diagnostic process. This history helps healthcare professionals understand the long-term pattern of ADHD symptoms. A comprehensive diagnosis often involves a multimodal assessment, incorporating information from multiple sources, including parents, teachers, caregivers, and the individual being evaluated. This holistic approach helps ensure a more accurate diagnosis. Advancements in diagnosis also recognize the importance of considering cultural factors and variations in symptom presentation. ADHD may manifest differently in individuals from diverse cultural backgrounds. This factor will help in the development of the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.

Development of New Medications

While stimulant medications have traditionally been the primary treatment for ADHD, there is growing interest in non-stimulant alternatives. Non-stimulant medications, such as atomoxetine (Strattera) and guanfacine (Intuniv), have been developed and approved for the treatment of ADHD. These medications work through different mechanisms and may be preferred in cases where stimulants are not suitable due to side effects or patient preferences. Extended-release formulations of ADHD medications are designed to provide symptom control throughout the day, reducing the need for multiple doses. These formulations improve convenience and compliance. For example, long-acting methylphenidate and amphetamine products are available. Prodrugs are compounds that are converted into active medications within the body. Some pharmaceutical companies are developing prodrug formulations of ADHD medications to enhance efficacy, reduce side effects, and improve the duration of action. Advances in drug delivery technology have led to the development of innovative delivery systems for ADHD medications. These include transdermal patches and controlled-release formulations that release the medication gradually over time. Researchers are exploring alternative mechanisms of action to target ADHD symptoms. For example, certain medications are designed to modulate neurotransmitters other than dopamine and norepinephrine, such as glutamate or histamine receptors.

Some pharmaceutical companies are investigating combination therapies, where two or more medications with different mechanisms of action are combined to enhance efficacy and address multiple aspects of ADHD symptoms. There is a growing interest in non-prescription and dietary supplement options for ADHD management. While these products are not medications, some individuals use them as complementary or alternative treatments. Patient-centered care is becoming increasingly important in ADHD treatment. Medications that offer flexibility in dosing, fewer side effects, and better tolerability are prioritized to align with individual patient preferences and needs. Advances in genetics and biomarker research may lead to the identification of specific markers or genetic factors that can help tailor medication choices to individual patients. The development of ADHD medications includes efforts to improve safety profiles, minimize side effects, and reduce the potential for misuse or abuse, particularly in the case of stimulant medications. Researchers are conducting long-term studies to better understand the effects of ADHD medications in the long run, particularly into adulthood, as ADHD is a lifelong condition. This factor will pace up the demand of the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.

Increasing Prevalence of ADHD

Greater awareness and understanding of ADHD among healthcare professionals, educators, parents, and the public have led to increased recognition of the condition. As people become more knowledgeable about ADHD, they are more likely to seek help and diagnosis. Advances in diagnostic criteria and assessment tools have made it easier to identify ADHD in individuals. Healthcare providers now have more accurate and standardized methods for diagnosing the condition. Efforts to reduce the stigma surrounding mental health conditions, including ADHD, have encouraged individuals and families to seek help without fear of judgment. This has contributed to higher diagnosis rates. Early intervention is essential in managing ADHD effectively. As awareness grows, more children are being diagnosed and receiving appropriate interventions, which can lead to better outcomes. While ADHD is often associated with children, there is also a growing recognition of ADHD in adolescents and adults. This expanded age range has increased the overall prevalence of ADHD diagnoses. Some environmental factors, such as exposure to certain toxins or prenatal factors, have been studied in relation to ADHD. While the exact causes of ADHD are not fully understood, research into these factors may contribute to an increased understanding of the condition. Research suggests that genetics play a role in the development of ADHD. As genetic studies advance, it may become easier to identify individuals at risk and diagnose the condition. ADHD is recognized as a global condition, and its prevalence is not limited to any specific region or country. As globalization continues, the prevalence of ADHD is likely to increase in different parts of the world. This factor will accelerate the demand of the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.

Key Market Challenges

Stigma and Awareness

Stigma often arises from misconceptions and stereotypes about ADHD. Some people believe that ADHD is not a real medical condition or that it is simply a result of laziness or poor parenting. This can lead to individuals with ADHD facing discrimination or judgment. Stigma can deter individuals and their families from seeking help for ADHD. They may fear being labeled, misunderstood, or stigmatized by others, which can delay diagnosis and treatment. Stigmatization can negatively affect the self-esteem and self-worth of individuals with ADHD. They may internalize negative beliefs about themselves, which can hinder their personal and academic development. Lack of awareness about ADHD can lead to late or missed diagnoses, particularly in adults. Many individuals may not recognize their symptoms as signs of ADHD, and healthcare providers may not consider it as a potential diagnosis. Limited awareness can contribute to both underdiagnosis and overdiagnosis of ADHD. Some individuals with ADHD may go undiagnosed, while others may be misdiagnosed due to a lack of understanding about the condition. Stigmatization can lead to social isolation for individuals with ADHD, as they may be excluded or bullied by peers. This isolation can have long-term psychological and emotional consequences.

Side Effects and Tolerance

Many medications used to treat ADHD, particularly stimulant medications like methylphenidate and amphetamines, can cause side effects. Common side effects may include insomnia, decreased appetite, weight loss, increased heart rate, and nervousness. Side effects can significantly impact an individual's quality of life, especially when they are bothersome or severe. For example, sleep disturbances can affect daily functioning and well-being. Side effects may lead to poor adherence to medication regimens. If individuals experience uncomfortable or undesirable side effects, they may be less likely to take their medications as prescribed or may discontinue treatment altogether. Side effects can vary from person to person. What may be tolerable for one individual may be intolerable for another. Healthcare providers must work closely with patients to find the most suitable medication and dosage.

Some individuals with ADHD who take stimulant medications may develop a tolerance over time. This means that the initial dosage that was effective may become less effective, requiring dosage adjustments or medication changes. Managing tolerance can be challenging, as healthcare providers need to strike a balance between maintaining symptom control and minimizing the risk of side effects or overmedication. Tolerance can lead to misuse or abuse of ADHD medications. Some individuals may take higher doses than prescribed to maintain the desired effects, which can have serious health consequences.

Key Market Trends

Behavioral Therapies

Behavioral therapies provide a comprehensive approach to managing ADHD symptoms. They focus on developing specific skills, strategies, and behaviors to help individuals with ADHD function more effectively in various settings, such as school, home, and work. Behavioral therapies address the core symptoms of ADHD, including inattention, impulsivity, and hyperactivity. They teach individuals how to better manage these symptoms in their daily lives. These therapies teach practical skills such as organization, time management, problem-solving, and impulse control. These skills are essential for individuals with ADHD to succeed in academics, work, and relationships. Behavioral therapies often use positive reinforcement techniques to reward desired behaviors. This can motivate individuals with ADHD to develop and maintain positive habits. Behavioral therapies often involve parents and family members, providing them with strategies to support the individual with ADHD at home and in other environments.

Behavioral interventions are tailored to the specific needs and challenges of everyone with ADHD. This individualization ensures that the therapy is effective and relevant to the person's life. Behavioral therapies can lead to long-term improvements in functioning and behavior. They equip individuals with ADHD with lifelong skills for self-management. In some cases, behavioral therapies can reduce the need for or complement the effects of medication, offering individuals and their families alternative treatment options. Behavioral interventions are often used in educational settings to support students with ADHD. These interventions can improve academic performance and classroom behavior. Learning and successfully applying behavioral strategies can boost the self-esteem and confidence of individuals with ADHD, reducing feelings of frustration and failure.

Segmental Insights

Drug Type Insights

In 2022, the Global Attention Deficit Hyperactivity Disorder (ADHD) Market largest share was held by stimulant drug type segment and is predicted to continue expanding over the coming years. Stimulant medications, such as methylphenidate (e.g., Ritalin) and amphetamines (e.g., Adderall), have historically been considered some of the most effective treatments for managing ADHD symptoms. They often provide rapid and noticeable improvements in attention, focus, and impulse control. Stimulant medications for ADHD have been in use for several decades and have a well-established track record of efficacy. This long history of use has built confidence among healthcare providers and patients. Stimulant drugs typically have a rapid onset of action, providing relief from ADHD symptoms within a relatively short time frame, which can be especially important for individuals seeking immediate symptom relief. Stimulant medications have been extensively researched and studied in clinical trials, providing a robust body of evidence supporting their effectiveness and safety. Stimulant medications can often be tailored to an individual's needs through dose adjustments, allowing healthcare providers to find the most effective and well-tolerated dosage for each patient.

Distribution Channel Insights

In 2022, the Global Attention Deficit Hyperactivity Disorder (ADHD) Market largest share was held by retail pharmacy segment in the forecast period and is predicted to continue expanding over the coming years. Retail pharmacies are easily accessible to the public. They are typically located in communities, often near residential areas, making it convenient for individuals and families to obtain ADHD medications. Many ADHD medications, especially stimulant-based medications like methylphenidate and amphetamines, require a prescription. Retail pharmacies are primary points of access for patients to fill these prescriptions. Pharmacists play a crucial role in patient education. They can provide information about the proper use of medications, potential side effects, and tips for managing ADHD symptoms. This education is essential for patients and caregivers. Retail pharmacies offer services for medication management, including dosage packaging, prescription refills, and reminders for patients to take their medications as prescribed. Retail pharmacies often have systems in place to process insurance claims, making it easier for patients to access their medications through their health insurance plans. In addition to prescription medications, retail pharmacies may also carry over the counter (OTC) products, such as dietary supplements and vitamins, that are marketed as supportive treatments for ADHD symptoms.

Regional Insights

The North America region dominates the Global Attention Deficit Hyperactivity Disorder (ADHD) Market in 2022. North America, particularly the United States and Canada, has consistently had high rates of ADHD diagnosis. This can be attributed to factors such as increased awareness, access to healthcare, and a well-established healthcare system. North America boasts a strong healthcare infrastructure with well-developed medical facilities, a high number of healthcare providers, and access to advanced diagnostic tools. This facilitates the identification and treatment of ADHD. There has been a significant effort in North America to raise awareness about ADHD among healthcare professionals, educators, and the public. This has led to more individuals seeking diagnosis and treatment. The pharmaceutical industry in North America, especially in the United States, plays a pivotal role in the ADHD market. Many leading pharmaceutical companies are headquartered in the U.S. and have developed and marketed ADHD medications.

Key Market Players

Supernus Pharmaceuticals, Inc.

Pfizer Inc

Novartis AG

Eli Lilly and Company

GlaxoSmithKline PLC

Johnson & Johnson

Hisamitsu Pharmaceutical Co., Inc.

Chongqing Fujin Biology Medical Company

Purdue Pharma LP

Mallinckrodt Pharmaceuticals

Report Scope:

In this report, the Global Attention Deficit Hyperactivity Disorder (ADHD) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Attention Deficit Hyperactivity Disorder (ADHD) Market, By Drug Type:

  • Stimulant
  • Non-stimulant

Attention Deficit Hyperactivity Disorder (ADHD) Market, By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Attention Deficit Hyperactivity Disorder (ADHD) Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.

Available Customizations:

  • Global Attention Deficit Hyperactivity Disorder (ADHD) Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Stimulant, Non-stimulant)
    • 5.2.2. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. India Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Australia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel
    • 6.3.4. Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Type
        • 6.3.4.2.2. By Distribution Channel
    • 6.3.5. South Korea Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Type
        • 6.3.5.2.2. By Distribution Channel

7. Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Germany Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Spain Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. North America Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Mexico Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Canada Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel

9. South America Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Attention Deficit Hyperactivity Disorder (ADHD) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Supernus Pharmaceuticals Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Pfizer Inc
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Novartis AG
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Eli Lilly and Company
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. GlaxoSmithKline PLC
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Mallinckrodt Pharmaceuticals
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Johnson & Johnson
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Hisamitsu Pharmaceutical Co., Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Chongqing Fujin Biology Medical Company
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Purdue Pharma LP
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer